On August 21, Peijia Medical announced its 2026 interim results. In the first half of 2026, revenue increased 20.1% year on year to RMB424.5 million, while gross profit rose 17.1% to RMB290.0 million. EBITDA and profit before tax both turned positive at RMB47.4 million and RMB0.7 million, respectively, marking the Group’s first-ever profit before tax. Net loss narrowed 87.4% to RMB9.0 million, while net cash generated from operating activities reached RMB49.4 million. 

The transcatheter valve therapeutic business generated RMB207 million in revenue, up 28.3%, with approximately 2,830 TAVR implantations, up 36.5%. TaurusTrio® continued its rapid ramp-up, exceeding 660 implantations in the first half. Neurointerventional revenue increased 13.3% to RMB217.2 million, while segment profit rose 79.0% to RMB73.2 million. Selling, administrative and R&D expense ratios all declined year on year, reflecting increasing economies of scale. 

Following the strong first-half TAVR performance, management raised its fullyear implantation guidance from approximately 5,000 to 6,000–6,500, while increasing its AR implantation guidance from no less than 1,500 to no less than 2,500.

 Honors  For more information, please visit:  https://finance.yahoo.com/healthcare/articles/peijia-medical-announces- 2026-interim-120000859.html